Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-22T14:06:32.309Z Has data issue: false hasContentIssue false
  • English
  • Français

Fluvoxamine/Pimozide Treatment of Concurrent Tourette's and Obsessive-Compulsive Disorder

Published online by Cambridge University Press:  02 January 2018

Pedro L. Delgado ,
Wayne K. Goodman ,
Lawrence H. Price ,
George R. Heninger  and
Dennis S. Charney
Pedro L. Delgado*
Affiliation:
Department of Psychiatry, Yale University School of Medicine, West Haven Veterans Administration Medical Center, West Haven, Connecticut 06516, USA
Wayne K. Goodman
Affiliation:
Department of Psychiatry, Yale University School of Medicine, Clinical Neuroscience Research Unit, Connecticut Mental Health Center, 34 Park Street, New Haven, Connecticut 06508
Lawrence H. Price
Affiliation:
Department of Psychiatry, Yale University School of Medicine, Clinical Neuroscience Research Unit, Connecticut Mental Health Center, 34 Park Street, New Haven, Connecticut 06508
George R. Heninger
Affiliation:
Department of Psychiatry, Yale University School of Medicine, Clinical Neuroscience Research Unit, Connecticut Mental Health Center, 34 Park Street, New Haven, Connecticut 06508
Dennis S. Charney
Affiliation:
Department of Psychiatry, Yale University School of Medicine, West Haven Veterans Administration Medical Center
*
∗Correspondence
Get access Rights & Permissions [Opens in a new window]

Abstract

A 25–year-old man with a history of Tourette's syndrome presented for treatment of OCD symptoms. Fluvoxamine worsened tics, led to coprolalia, and did not help the OCD. The addition of pimozide dramatically reduced both OCD and Tourette's symptoms. Double-blind sequential discontinuation of fluvoxamine and pimozide confirmed that pimozide alone reduced only tics and the combination of fluvoxamine and pimozide was required for the improvement in OCD. Tics may reflect a subtype of OCD. Some OCD patients unresponsive to a 5–HT reuptake inhibitor alone may benefit from the addition of a dopamine antagonist.

Type
Brief Reports
Information
The British Journal of Psychiatry , Volume 157 , Issue 5 , November 1990 , pp. 762 - 765
Copyright
Copyright © The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Caine, E. D., Polinski, R. J., Ebert, M. H., et al (1979) Trial of chlorimipramine and desipramine for Gilles de la Tourette's syndrome. Annals of Neurology, 5, 305–306.Google Scholar
Gabay, S. (1981) Serotonergic-dopaminergic interactions: implications for hyperkinetic disorders. In Advances in Experimental Medicine and Biology (eds. B. Haber, S. Gabay, M. R. Issidorides, et al). New York: Plenum Press.Google Scholar
Goodman, W. K., Price, L. H., Rasmussen, S. A., et al (1989a) Efficacy of fluvoxamine in obsessive compulsive disorder: a double-blind comparison with placebo. Archives of General Psychiatry, 46, 36–44.CrossRefGoogle ScholarPubMed
Goodman, W. K., Price, L. H., Rasmussen, S. A., et al (1989b) The Yale-Brown obsessive compulsive Scale (Y–BOCS): Part I. Development, use, and reliability. Archives of General Psychiatry, 46, 1006–1011.CrossRefGoogle Scholar
Goodman, W. K., Price, L. H., Delgado, P. L., et al (1990) Efficacy of serotonin reuptake inhibitors in the treatment of obsessive compulsive disorder: comparison of fluvoxamine and desipramine. Archives of General Psychiatry, 47, 577–585.CrossRefGoogle ScholarPubMed
Insel, T. R. & Murphy, D. L. (1981) The psychopharmacological treatment of obsessive-compulsive disorder: a review. Journal of Clinical Psychopharmacology, 1, 304–311.CrossRefGoogle ScholarPubMed
Korsgaard, S., Gerlach, J. & Christensson, E. (1985) Behavioral aspects of serotonin–dopamine interaction in the monkey. European Journal of Pharmacology, 118, 245–252.Google Scholar
Leckman, J. F., Towbin, K. E., Ort, S. I., et al (1988) Clinical assessment of tic disorder severity. In Tourette Syndrome and Tic Disorders: Clinical Understanding and Treatment (eds D. J. Cohen, R. Bruun & J. F. Leckman). New York: John Wiley.Google Scholar
Leonard, H., Swedo, S., Coffey, M., et al (1988) Clomipramine vs. desipramine in childhood obsessive compulsive disorder. Psychopharmacology Bulletin, 24, 93–95.Google Scholar
Pauls, D. L., Towbin, K. E., Leckman, J. F., et al (1986) Gilles de la Tourette's syndrome and obsessive-compulsive disorder: evidence supporting a genetic relationship. Archives of General Psychiatry, 43, 1180–1182.CrossRefGoogle ScholarPubMed
Pauls, D. L. & Leckman, J. F. (1986) The inheritance of Gilles de la Tourette's syndrome and associated behaviors: evidence for autosomal dominant transmission. New England Journal of Medicine, 315, 993–997.CrossRefGoogle ScholarPubMed
Riddle, M. A., Leckman, J. F., Hardin, M. T., et al (1988) Fluoxetine treatment of obsessions and compulsions in patients with Tourette's syndrome. American Journal of Psychiatry, 145, 1173–1174.Google Scholar
Shapiro, A. K. (1976) Psychochemotherapy. In Biological Foundations of Psychiatry (eds R. G. Grenell & S. Gabay). New York: Raven Press.Google Scholar
Sverd, J. (1988) Imipramine treatment of panic disorder in a boy with Tourette's syndrome. Journal of Clinical Psychiatry, 49, 31–32 Google Scholar
Thoren, P., Asberg, M., Cronholm, B., et al (1980) Clomipramine treatment of obsessive–compulsive disorder. Archives of General Psychiatry, 37, 1281–1285 CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.